Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Technology ID
TAB-4330

Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use

E-Numbers
E-025-2006-0
Lead Inventors
O'Keefe, Barry
Co-Inventors
McMahon, James
Mori, Toshiyuki
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Development Stages
Discovery
Lead IC
NCI
ICs
NCI

This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003).  Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection. 

Issued patents: US 8,088,729 (Jan. 3, 2012) and foreign rights in France, Germany, Ireland, United Kingdom, Switzerland (all granted)

Competitive Advantages:

  • Highly Potent Broad-Spectrum Antiviral Lectin
  • Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses.

Commercial Applications:

  • Microbicide that can prevent viral transmission
  • Therapeutic against enveloped virus-mediated diseases 

Request More Info

Licensing Contacts
Dick, Taryn
taryn.dick@nih.gov

Related Inventions

Patents

  • US
    Provisional (PRV) 60/741,403
    Filed on 2005-12-01
    Status: Abandoned
  • Patent Cooperation Treaty
    (PCT) PCT/US2006/045930
    Filed on 2006-12-01
    Status: Expired
  • US Patent 8,088,729
    Filed on 2008-05-30
    Status: Issued
  • European Patent
    National Stage 06838737.2
    Filed on 2006-12-01
    Status: Issued
  • European Patent
    Divisional (DIV) 10014894.9
    Filed on 2006-12-01
    Status: Abandoned
  • European Patent
    Divisional (DIV) 10014895.6
    Filed on 2006-12-01
    Status: Abandoned
  • European Patent
    Divisional (DIV) 10014893.1
    Filed on 2006-12-01
    Status: Abandoned
  • France
    European patent (EP) 06838737.2
    Filed on 2006-12-01
    Status: Issued
  • Germany
    European patent (EP) 06838737.2
    Filed on 2006-12-01
    Status: Issued
  • Ireland
    European patent (EP) 06838737.2
    Filed on 2006-12-01
    Status: Issued
  • United Kingdom
    European patent (EP) 06838737.2
    Filed on 2006-12-01
    Status: Issued
  • Switzerland
    European patent (EP) 06838737.2
    Filed on 2006-12-01
    Status: Issued

Publications

Collaborations

  • Licensing
  • Collaboration
Date Published